Free Trial

Avidity Biosciences (RNA) Stock Price, News & Analysis

Avidity Biosciences logo
$28.40 -0.63 (-2.17%)
As of 04:00 PM Eastern

About Avidity Biosciences Stock (NASDAQ:RNA)

Key Stats

Today's Range
$28.37
$29.73
50-Day Range
$26.07
$36.24
52-Week Range
$21.51
$56.00
Volume
946,287 shs
Average Volume
1.36 million shs
Market Capitalization
$3.42 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.59
Consensus Rating
Buy

Company Overview

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Avidity Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

RNA MarketRank™: 

Avidity Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 625th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Avidity Biosciences has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 16 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Avidity Biosciences has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Avidity Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avidity Biosciences is -9.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avidity Biosciences is -9.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Avidity Biosciences has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Avidity Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    14.10% of the float of Avidity Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently increased by 1.05%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Avidity Biosciences does not currently pay a dividend.

  • Dividend Growth

    Avidity Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.10% of the float of Avidity Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Avidity Biosciences has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Avidity Biosciences has recently increased by 1.05%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Avidity Biosciences has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Avidity Biosciences this week, compared to 8 articles on an average week.
  • Search Interest

    6 people have searched for RNA on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Avidity Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,229,820.00 in company stock.

  • Percentage Held by Insiders

    Only 3.83% of the stock of Avidity Biosciences is held by insiders.

  • Read more about Avidity Biosciences' insider trading history.
Receive RNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter.

RNA Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

RNA Stock Analysis - Frequently Asked Questions

Avidity Biosciences' stock was trading at $29.08 at the beginning of 2025. Since then, RNA stock has decreased by 2.3% and is now trading at $28.40.
View the best growth stocks for 2025 here
.

Avidity Biosciences, Inc. (NASDAQ:RNA) issued its earnings results on Thursday, May, 8th. The biotechnology company reported ($0.90) EPS for the quarter, missing analysts' consensus estimates of ($0.88) by $0.02. The biotechnology company earned $1.60 million during the quarter, compared to analysts' expectations of $2.63 million. Avidity Biosciences had a negative net margin of 4,136.00% and a negative trailing twelve-month return on equity of 26.96%.

Avidity Biosciences (RNA) raised $150 million in an IPO on Friday, June 12th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, SVB Leerink, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO.

Shares of RNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avidity Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Eli Lilly and Company (LLY), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/08/2025
Today
6/30/2025
Next Earnings (Estimated)
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RNA
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.59
High Stock Price Target
$96.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+130.9%
Consensus Rating
Buy
Rating Score (0-4)
3.06
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$322.30 million
Net Margins
-4,136.00%
Pretax Margin
-4,135.99%

Debt

Sales & Book Value

Annual Sales
$10.90 million
Price / Cash Flow
N/A
Book Value
$11.94 per share
Price / Book
2.38

Miscellaneous

Free Float
115,904,000
Market Cap
$3.42 billion
Optionable
Optionable
Beta
0.95

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:RNA) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners